Editas Medicine IPO
Editas Medicine is a leading genome editing company focused on developing CRISPR-based medicines for serious diseases. The company's pipeline includes treatments for inherited retinal dystrophies, sickle cell disease, and various cancers. Investors value its pioneering position in the CRISPR therapeutics space and partnerships with major pharmaceutical companies.
Key Facts
| Industry | Gene Editing |
| Founded | 2013 |
| Headquarters | Cambridge, MA |
| Employees | ~200 |
| Website | editasmedicine.com |
| Funding | Public company (NASDAQ: EDIT). IPO in 2016 raised $94M |
About Editas Medicine
Editas Medicine is a leading clinical-stage genome editing company focused on translating CRISPR technology into transformative medicines for people with serious diseases. The company was founded by pioneers of CRISPR technology and maintains one of the broadest intellectual property portfolios in the gene editing space, with a focus on both in vivo and ex vivo therapeutic approaches.
Editas is advancing multiple programs through clinical trials, including treatments for inherited blindness (EDIT-101), sickle cell disease, and various cancers. Their lead program for Leber congenital amaurosis 10 represents one of the first in vivo CRISPR trials, delivered directly to the eye. The company's platform encompasses multiple gene editing technologies beyond traditional CRISPR, including base editing and prime editing, positioning them to address a wide range of genetic diseases that were previously considered undruggable.
IPO Status
Editas Medicine went public in February 2016, raising approximately $94.4 million in its IPO on NASDAQ under the ticker EDIT. The company was among the first pure-play CRISPR companies to go public, generating significant investor interest in the emerging genome editing sector. Since its IPO, Editas has advanced multiple programs through clinical development and established strategic partnerships. The stock has experienced the typical volatility of clinical-stage biotech companies, with movements often tied to clinical trial results and regulatory developments in the gene editing space.
Competitors
Frequently Asked Questions
Does Editas Medicine have a stock?
Yes, Editas Medicine completed its IPO in February 2016. The company has been publicly traded on NASDAQ under the ticker EDIT for several years.
When is the Editas Medicine IPO date?
Editas Medicine already completed its IPO on February 3, 2016. The company is currently a publicly traded biotechnology stock on NASDAQ.
How can I buy Editas Medicine stock?
You can buy Editas Medicine stock through any brokerage account since it trades publicly on NASDAQ under the ticker EDIT. The shares are readily available for purchase during standard trading hours.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts